Skip to search formSkip to main contentSkip to account menu

EZN 3042

Known as: Survivin mRNA Antagonist EZN-3042, EZN-3042, EZN3042 
A locked nucleic acid (LNA) antisense oligonucleotide targeting survivin mRNA, with potential antineoplastic activity. EZN-3042 hybridizes to… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligonucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Mycobacterium abscessus diagnosed in hemoculture
A 23 y/o female admitted with complaints of fewer, dyspnea, and cough for a month. She was diagnosed systemic lupus erytematotus… 
2013
2013
Abstract 31: A population pharmacokinetic-pharmacodynamic (POP-PK/PD) modelling of EZN-3042 administered with or without docetaxel in patients with advanced solid tumors or lymphoma.
Background: Survivin, a member of the apoptosis protein inhibitor family, is an essential regulator of cell division and a… 
2011
2011
Results of a Phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin messenger ribonucleic acid (mRNA) antagonist, administered with or without…
A th W T l h 1 A it P t ik 1 K i k P P d l 1 J A 1 F i M L ki 2 K R ï 2 St K l b k † Ab B hbi d 3* Poster A216 n ony . o c er, m… 
2008
2008
A novel locked nucleic acid oligonucleotide against survivin, EZN-3042, inhibits survivin expression and causes antitumor effects
1) EZN-3042 displayed potent in vitro knockdown of survivin mRNA and growth inhibition of several human cancer cell lines (IC50… 
Review
2007
Review
2007
Effects of survivin and survivin inhibition in canine models of lymphoma and osteosarcoma
..................................................................................................................ii… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)